
|Videos|June 10, 2015 (Updated: November 11, 2020)
Nivolumab Effective in Advanced Non-Squamous NSCLC
Author(s)Luis Paz-Ares, MD
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Advertisement
In this video, Luis Paz-Ares, MD, discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), with the largest improvement seen in PD-L1-positive patients.
The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement


Optimizing the Use of Hypofractionated Radiotherapy in Lung Cancer Care
Published: | Updated:


OncoPrism-NSCLC Test Predicts Key Clinical Outcomes in Lung Cancer
Published: | Updated:

Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Traditional Approval to Encorafenib in BRAF-Mutated CRC
2
Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
3
FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer
4
Evaluating the Cost-Effectiveness of Immunotherapy in Lung Cancers
5








































